Evaluating the effects of two medications for high blood pressure
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension
PHASE3 · Addpharma Inc. · NCT06441630
This study is testing whether a combination of two new medications can help people with high blood pressure feel better and stay safe.
Quick facts
| Phase | PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 251 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | Addpharma Inc. (industry) |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06441630 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the efficacy and safety of the combined use of AD-227A and AD-227B in treating patients with essential hypertension. Participants will receive either the active medications or placebos to determine the effectiveness of the treatment regimen. The study is designed to gather data on how well these medications work together and their safety profile in a Phase 3 setting. The trial will involve a diverse group of patients who meet specific inclusion criteria.
Who should consider this trial
Good fit: Ideal candidates for this study are adults diagnosed with essential hypertension who can provide informed consent.
Not a fit: Patients with secondary hypertension will not benefit from this study as it specifically targets essential hypertension.
Why it matters
Potential benefit: If successful, this study could provide a new effective treatment option for patients suffering from essential hypertension.
How similar studies have performed: Other studies have shown promise in the treatment of essential hypertension with similar medication combinations, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed informed consent * Patients with Essential Hypertension * Other inclusions applied Exclusion Criteria: * Patient with Secondary Hypertension * Other exclusions applied
Where this trial is running
Seoul
- Gangnam CHA Medical Center — Seoul, South Korea (RECRUITING)
Study contacts
- Principal investigator: Chong-Jin Kim — Gangnam CHA Medical Center
- Study coordinator: JeongEun Park
- Email: parkje@addpharma.co.kr
- Phone: +82-31-891-6989
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Essential Hypertension